Table 5.
Summary of preclinical studies of targeted hybrid gamma–NIR fluorescent probes identified in the literature survey arranged by year of publication
| Target | Fluorescent component | Nuclear component | Year | Refs |
|---|---|---|---|---|
| HER-2 Breast, ovary, endometrium, bladder, lung, colon, H&N [30] |
IRDye 800CWa | 64Cu (β) | 2010 | [59] |
| αvβ3 integrin Tumour angiogenesis |
CyAL-5.5b | 111In (γ) | 2012 | [68] |
| EpCAM Prostate |
IRDye 800CWl | 64Cu (β) | 2012 | [53] |
| CD105 (endoglin) Breast, pancreatic, prostate, brain |
IRDye 800CWl | 89Zr (β) | 2012 | [60] |
| EpCAM Prostate |
IRDye 800CWl | 64Cu (β) | 2013 | [64] |
| CD206 Sentinel nodes |
IRDye 800CWl | 68Ga (β) | 2013 | [65] |
| GLP-1R Insulinomas, β-cells |
Cy5b | 64Cu (β) | 2014 | [66] |
| EphB4 Glioblastoma |
Cy5.5c | 64Cu (β) | 2014 | [61] |
| PSMA Prostate |
IRDye 800CWl | 111In (γ) | 2014 | [54] |
| CEA Colorectal |
IRDye 800CWl | 111In (γ) | 2014 | [69] |
| uPAR Colorectal, breast, pancreatic |
ZW800-1 | 111In (γ) | 2015 | [57] |
| CAIX Clear cell renal cell carcinoma |
IRDye 800CWl | 111In (γ) | 2015 | [55] |
| CD206 Sentinel nodes |
IRDye 800CWl |
68Ga (β) 99mTc (γ) |
2015 | [67] |
| Bacterial infection | Cy5 | 111In (γ) | 2015 | [63] |
| αvβ3 integrin Tumour angiogenesis, colon adenocarcinoma |
Cy5.5 | 99mTc (γ) | 2016 | [70] |
| CAIX Clear cell renal cell carcinoma |
IRDye 800CWl | 111In (γ) | 2016 | [56] |
| sst2
Neuroendocrine |
Cy5 | 111In (γ) | 2016 | [58] |
Note that only articles describing specific probes are included, not those that solely described generic platforms for use with different targets, fluorescent or gamma components or those that compare multiple probes. Nuclear components have been labelled as gamma emitting (γ) or positron emitting (β)
aLI-COR Biosciences
bLumiprobe
cAmersham Pharmacia Biotech